2295 KB47 KB200520252022Martinc, Boštjanštevilka:2letnik:73str. 115-127COBISSID_HOST:140694531ISSN:2536-4316URN:URN:NBN:SI:doc-92M791BQslSlovensko farmacevtsko društvoFarmacevtski vestnikcardiovascular outcomesGLP-1 receptor agonistsledvični izidireceptorski agonisti GLP-1renal outcomesSGLT2 inhibitorsSladkorna bolezensladkorna bolezen tipa 2srčno-žilni iziditype 2 diabeteszaviralci SGLT2Novosti pri zdravljenju z zaviralci SGLT2 in agonisti receptorjev GLP-1| Novelties in the treatment of SGLT2 inhibitors and GLP-1 receptor agonists|Type 2 diabetes is one of the most common chronic non-communicable diseases. Due to its frequency, demanding and complex treatment and severe consequences, it represents a major health, social and economic problem. The main causes of morbidity and mortality in type 2 diabetic patients are cardiovascular diseases, which, in addition to classic risk factors such as hypertension, obesity, dyslipidemia, albuminuria and smoking, are also independently affected by diabetes related heart failure and diabetic kidney disease. With the multifactorial approach to treatment and the introduction of GLP-1 receptor agonists and SGLT2 inhibitors, the treatment of diabetes has improved significantly. As a result, cardiovascular morbidity and mortality have been significantly reduced, thus also improving the health-related quality of life of diabetic patients. The introduction of GLP-1 receptor agonists and SGLT2 inhibitors represents a new milestone, not only in the management of diabetes, but also in reducing the incidence and hospitalization due to the worsening of heart failure and preventing the development and progression of chronic kidney diseaseSladkorna bolezen tipa 2 je ena izmed najpogostejših kroničnih nenalezljivih bolezni. Zaradi svoje pogostosti, zahtevne in kompleksne obravnave ter težkih posledic predstavlja velik zdravstveni, socialni in ekonomski problem. Poglavitni vzrok obolevnosti in visoke umrljivosti bolnikov s sladkorno boleznijo tipa 2 predstavljajo srčno-žilne bolezni, na katere poleg klasičnih dejavnikov tveganja, kot so arterijska hipertenzija, debelost, dislipidemija, albuminurija in kajenje, neodvisno vplivata tudi s sladkorno boleznijo povezano srčno popuščanje in diabetična ledvična bolezen. Z multifaktorskim pristopom zdravljenja ter vpeljavo novih učinkovin iz razredov receptorskih agonistov GLP-1 ter zaviralcev SGLT2 se je obravnava sladkorne bolezni pomembno izboljšala. Posledično sta se znatno zmanjšali srčno-žilna obolevnost in umrljivost, hkrati pa se je izboljšala z zdravjem povezana kakovost življenja. Uvedba receptorskih agonistov GLP-1 in zaviralcev SGLT2 predstavlja nov mejnik, ne samo pri obvladovanju sladkorne bolezni, temveč tudi v zmanjšanju pojavnosti hospitalizacij zaradi poslabšanja srčnega popuščanja ter preprečevanju razvoja in napredovanja kronične ledvične bolezniTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko farmacevtsko društvo